Bevacizumab
- Generic Name
- Bevacizumab
- Brand Names
- Avastin, Mvasi, Oyavas, Alymsys, Aybintio, Abevmy, Vegzelma, Onbevzi, Zirabev, Lytenava, Avzivi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 216974-75-3
- Unique Ingredient Identifier
- 2S9ZZM9Q9V
- Background
There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells. VEGF plays an important role in angiogenesis, lymphangiogenesis, and tumor growth, which are all factors that contribute to its attractiveness as a therapeutic target for anti-cancer therapies.
...
- Indication
As a vascular endothelial growth factor (VEGF) inhibitor, bevacizumab is used in several chemotherapy regimens to treat metastatic colorectal cancer; metastatic, unresectable, locally advanced or recurrent non-squamous non-small cell lung cancer; metastatic renal cell carcinoma; metastatic, persistent, or recurrent cervical cancer; primary peritoneal cancer;...
- Associated Conditions
- Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Colorectal Cancer (CRC), Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Persistent Cervical Cancer, Recurrent Cervical Cancer, Recurrent Glioblastoma, Relapsed Glioblastoma, Stage III Fallopian Tube Cancer, Stage III Ovarian Epithelial Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Primary Peritoneal Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent Non-Squamous Non-Small Cell Lung Cancer, Recurrent Platinum-Sensitive Epithelial Ovarian Cancer, Recurrent Platinum-resistant Epithelial Ovarian Cancer, Recurrent platinum drug resistant Fallopian tube cancer, Recurrent platinum drug resistant primary peritoneal cancer, Recurrent platinum sensitive primary peritoneal cancer, Recurrent platinum-sensitive fallopian tube cancer, Unresectable Non-Squamous Non-Small Cell Lung Cancer, Unresectable, advanced Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
- Associated Therapies
- First Line Chemotherapy, First or Second Line Therapy, Second Line Treatment
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- Conditions
- Interventions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20605
- Registration Number
- NCT05834348
- Locations
- 🇳🇴
Pfizer Norway, Oslo, Norway
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Onward Therapeutics
- Target Recruit Count
- 150
- Registration Number
- NCT05828459
- Locations
- 🇫🇷
Saint-Eloi Hospital - Montpellier (CHU), Montpellier, France
🇫🇷Saint-Joseph Hospital - Paris, Paris, France
🇫🇷ICM - Montpellier, Montpellier, France
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- GI Innovation, Inc.
- Target Recruit Count
- 358
- Registration Number
- NCT05824975
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Minnesota, Rochester, Minnesota, United States
ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- MEI Pharma, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT05824559
- Locations
- 🇺🇸
Rutgers University, New Brunswick, New Jersey, United States
🇺🇸Mt Sinai New York, New York, New York, United States
🇺🇸Vanderbilt -Ingram Cancer Center, Nashville, Tennessee, United States
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05799820
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Guangzhou Gloria Biosciences Co., Ltd.
- Target Recruit Count
- 424
- Registration Number
- NCT05798819
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 396
- Registration Number
- NCT05797168
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT05797246
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Adjuvant Chemotherapy Combined With Targeted Therapy or Not in the T3-4N2 Colorectal Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2023-05-24
- Target Recruit Count
- 366
- Registration Number
- NCT05797467
- Locations
- 🇨🇳
The Sixth Affiliate Hospital of Sun Yat-Sen University, GuangZhou, Guangdong, China
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-10-11
- Target Recruit Count
- 156
- Registration Number
- NCT05781308
- Locations
- 🇫🇷
CHU Amiens, Amiens, France
🇫🇷CHU Besançon - Hôpital J. MINJOZ, Besançon, France
🇫🇷Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.